Ibex® Design Scaffolds and other Recombinant Proteins

An integrated drug substance/drug product DNA-to-IND offering delivering tailored product-specific solutions for scaffolds and other recombinant proteins, with reliable timelines backed by Lonza’s decades of experience in biologics.

Talk to our experts

Interleukin vial hand - rebrand

15 months* from DNA to IND/IMPD

10 months* from DNA to tox Drug Substance

11 months* from DNA to tox Drug Product

Tailorable technical scope and timelines when necessary to meet your development needs

Take your molecule from DNA to tox drug substance in only 10 months* and IND in 15 months*

Recombinant proteins that do not contain an Fc region, or have an affinity resin available, typically do not fit platform methods developed for mAb-type products. They often have product-specific requirements that impact the development strategy.

Benefit from Lonza’s experienced project teams and subject matter experts with a wealth of knowledge from working on these types of molecules, who can tailor a development strategy to meet your product-specific needs.

*From DNA transfection to Delivery of IND-Enabling CMC Modules. Indicative timelines. Subject to molecule evaluation and terms & conditions.

Related Insights

Visit Knowledge Center

Webinar (on-demand)

Tailored CMC Solutions Meeting the Needs of Novel Molecular Biologic Formats

Antibodies still predominate in the clinic, however there is a large shift in drug development pipelines to more complex, next generation biologics,...

CMC Solutions to Meet the Product-Specific Needs of Novel Molecular Biologic Formats

Antibodies still predominate in the clinic, however there is a large shift in drug development pipelines to more complex, next generation biologics,...

Q&A: An Inside Look At CMC Strategy Development For Novel Biologic Formats

An increasing number of complex, next-generation biologics in today’s development pipelines are fueling hope of addressing a wide range of unmet...

Visit Knowledge Center

Latest news

View all articles

Lonza Announces First GMP Batch Completion at Next-Generation Mammalian Manufacturing Facility in...

Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine...

Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of...

Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)

Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of...

Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH)

View all articles

Sign up. Stay up-to-date.